What is Epigenic Therapeutics?
Epigenic Therapeutics is a frontier biotechnology enterprise founded in 2021 by a cohort of distinguished scientists. The company specializes in the development of next-generation gene editing therapies that target the regulation of epigenetic genomes. By focusing on the underlying mechanisms of gene expression rather than permanent DNA alteration, the firm is pioneering novel interventions for a diverse array of indications, including ocular, neurodegenerative, metabolic, and rare diseases. With a robust product pipeline, Epigenic Therapeutics is strategically positioned at the intersection of precision medicine and genomic innovation, aiming to address significant unmet medical needs through highly specific, programmable therapeutic candidates.
How much funding has Epigenic Therapeutics raised?
Epigenic Therapeutics has raised a total of $112M across 3 funding rounds:
Other Financing Round
$20M
Series A
$32M
Series B
$60M
Other Financing Round (2022): $20M with participation from Fountainbridge Capital, Trinity Innovation Fund, Kingray Capital, Morningside Venture Capital, and TigerYeah Capital
Series A (2023): $32M led by Qiming Venture Partners, Morningside Venture Capital, and OrbiMed
Series B (2025): $60M supported by IFSC Group, OrbiMed, and Qiming Venture Partners
Key Investors in Epigenic Therapeutics
OrbiMed
OrbiMed is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms with a deep understanding of life sciences innovation cycles.
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm that invests in innovative companies across technology and healthcare, providing strategic guidance and industry resources to foster long-term growth.
Morningside Venture Capital
Morningside Venture Capital is a Hong Kong-based private equity and venture capital firm established in 1986, specializing in early-stage technology and high-growth company investments.
What's next for Epigenic Therapeutics?
With the successful closure of this major enterprise-level funding round, Epigenic Therapeutics is poised to accelerate its clinical development programs and expand its research infrastructure. The strategic deployment of this capital will likely focus on transitioning lead candidates through critical regulatory milestones and scaling manufacturing capabilities to support future clinical trials. As the company matures, the focus will shift toward establishing commercial partnerships and refining its proprietary technology to ensure scalability across its diverse therapeutic portfolio. Investors remain optimistic that the firm's unique approach to epigenetic modulation will provide a sustainable competitive advantage in the global gene therapy market, potentially leading to transformative outcomes for patients suffering from previously intractable diseases.
See full Epigenic Therapeutics company page
